Saturday, July 11, 2026

pharma · Androgenetic Alopecia · Acute Myocardial Infarction

Dong Wang

Dong Wang clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
8
Drugs
13
Patents
0
Intelligence · Clinical Programs

Dong Wang projects

8 ClinicalTrials.gov programs sponsored by Dong Wang.

Dong Wang has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Telmisartan/Amlodipine

    Dong Wang

    Hypertension With Hyperlipidemia

    phase 3 small molecule completed

    1 trial
  2. evogliptin

    Dong Wang

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  3. DA-4001C

    Dong Wang

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial
  4. Aricept 5mg Tablet

    Dong Wang

    Healthy

    phase 1 small molecule active

    1 trial
  5. DA-5210 10/500mg

    Dong Wang

    Healthy

    phase 1 small molecule completed

    1 trial
  6. De-escalation strategy

    Dong Wang

    Acute Myocardial Infarction

    approved small molecule active

    1 trial
  7. Risedronate Sodium 35 MG [Actonel]

    Dong Wang

    Postmenopausal Osteoporosis

    approved small molecule completed

    1 trial
  8. rivastigmine patch

    Dong Wang

    Alzheimer's Disease

    small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Dong Wang have?

8 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.